Experimental CAR-T therapy takes on Hard-to-Treat myeloma
NCT ID NCT05577000
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial is testing a new type of immune cell therapy called Anti-BCMA CAR-T cells in 5 adults with multiple myeloma that has come back or not responded to at least three prior treatments. The therapy involves collecting a patient's own immune cells, modifying them to target a protein on myeloma cells, and infusing them back along with two chemotherapy drugs. The main goal is to check safety and find the right dose, not yet to prove it works.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Anti-BCMA CAR-T cells (a type of immune cell therapy) given with chemotherapy drugs fludarabine and cyclophosphamide
What this could lead to
If this works, it could point toward a new treatment option for people with multiple myeloma that has stopped responding to other therapies.
What could go wrong
This is a very early, small phase 1b trial with only 5 participants, focused mainly on safety. The treatment may not work, and there are risks of serious side effects like cytokine release syndrome or nerve problems.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of California, San Francisco
San Francisco, California, 94143, United States